Triamcinolone acetonide suprachoroidal injectable suspension - Clearside Biomedical

Drug Profile

Triamcinolone acetonide suprachoroidal injectable suspension - Clearside Biomedical

Alternative Names: CLS-1001; CLS-1003; CLS-1004; CLS-TA; ZUPRATA

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Clearside Biomedical
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Retinal oedema; Uveitis
  • Phase I/II Diabetic macular oedema
  • No development reported Ocular inflammation

Most Recent Events

  • 14 Mar 2017 Clearside Biomedical plans a phase II trial to compare triamcinolone acetonide in combination with intravitreal aflibercept to intravitreal aflibercept monotherapy in patients with Diabetic macular oedema over in mid of 2017
  • 01 Mar 2017 Clearside Biomedical receives patent allowance for triamcinolone acetonide in USA
  • 09 Jan 2017 Clearside Biomedical initiates enrolment in a non interventional trial for Retinal oedema (macular oedema associated with retinal vein occlusion) in USA (NCT02956330)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top